UCB expands immunology pipeline with 2.2 billion USD acquisition of Candid Therapeutics

UCB has entered into a definitive agreement to acquire clinical-stage biotech firm Candid Therapeutics for an upfront payment of $2 billion. The deal centers on cizutamig, a novel T-cell engager designed to reset the immune system in patients with severe autoimmune and inflammatory diseases.

UCB, a Brussels-based global biopharmaceutical leader, has announced the acquisition of Candid Therapeutics in a transaction valued at up to $2.2 billion, including $200 million in potential milestones. According to official disclosures, the deal is expected to close between late Q2 and early Q3 2026, pending antitrust clearance. UCB specializes in neurology and immunology, while Candid Therapeutics is a clinical-stage biotechnology company focused on utilizing T-cell engagers (TCEs) to treat immune-mediated conditions.

This development is significant as it integrates cizutamig, a bispecific antibody targeting BCMA and CD3, into UCB’s portfolio. Unlike traditional therapies, this asset is engineered to deplete pathogenic B-cell populations while minimizing systemic cytokine release. By securing this platform, UCB is pivoting toward "immune reset" strategies-treatments that aim for long-term disease remission rather than mere symptom management. This follows a previous agreement with Antengene, signaling a concerted effort by UCB to dominate the next generation of antibody-mediated autoimmune therapies.

For the biopharmaceutical and venture capital sectors, this acquisition underscores the high market value of multi-specific antibody platforms. The move directly impacts the competitive landscape for autoimmune treatments, challenging existing biologics and JAK inhibitors. For investors, the $2 billion upfront commitment reflects UCB’s confidence in the clinical data of cizutamig, which has already been evaluated in over 100 patients. Strategically, the deal provides UCB with a modular, multi-antigen strategy that reduces reliance on any single modality, potentially establishing a new benchmark for standard of care in underserved, severe inflammatory indications.